BACKGROUND: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). CASE REPORT: Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma. CONCLUSION: These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed.
BACKGROUND: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). CASE REPORT: Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma. CONCLUSION: These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed.
Authors: Andrea Varrone; Katarina Varnäs; Aurelija Jucaite; Zsolt Cselényi; Peter Johnström; Magnus Schou; Ana Vazquez-Romero; Mohammad M Moein; Christer Halldin; Andrew P Brown; Karthick Vishwanathan; Lars Farde Journal: J Cereb Blood Flow Metab Date: 2019-04-20 Impact factor: 6.200
Authors: Gustavo Chagoya; Shawn G Kwatra; Cory W Nanni; Callie M Roberts; Samantha M Phillips; Sarah Nullmeyergh; Samuel P Gilmore; Ivan Spasojevic; David L Corcoran; Christopher C Young; Karla V Ballman; Rohan Ramakrishna; Darren A Cross; James M Markert; Michael Lim; Mark R Gilbert; Glenn J Lesser; Madan M Kwatra Journal: Oncotarget Date: 2020-06-02